Public Option Headed for Senate Death
Looks like the insurance companies are getting what they've paid for in the U.S. Congress. The Senate Finance Committee is closer to a deal with Republicans, which means no public health care option. The Blue Dogs, meanwhile, are still nipping at the heels of House Democrats.
Looks like the insurance companies are getting what they’ve paid for in the U.S. Congress. The Senate Finance Committee is closer to a deal with Republicans, which means no public health care option. The Blue Dogs, meanwhile, are still nipping at the heels of House Democrats.
Your support matters…Reuters via New York Times:
The Senate Finance negotiations have zeroed in on a plan that would use non-profit cooperatives to compete with private insurers to drive down costs, members say, not the public plan favoured by Obama and many Democrats.
The panel also is likely to back a tax on high-cost insurance policies to try to raise revenue and keep costs down.
Independent journalism is under threat and overshadowed by heavily funded mainstream media.
You can help level the playing field. Become a member.
Your tax-deductible contribution keeps us digging beneath the headlines to give you thought-provoking, investigative reporting and analysis that unearths what's really happening- without compromise.
Give today to support our courageous, independent journalists.
TD Original
Reflecting on the systems that maintain racism and separatism in America.
Wounds of War
According to Pentagon policy on “responding to civilian harm”, Defense Secretary Lloyd Austin owes Somalian drone victims an overdue apology.
Editorial Cartoons
Politics
Obama's only takeaway from the Syria episode was to never again seek Congressional approval for military action.
Politics
Cautionary politics lost them the majority a decade ago. It’s taken that long to reboot.
With his nonstop barrage of lies, the president has degraded our electoral system to the point that any result will feel illegitimate.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.